Hiroshi Yamamoto

Managing Director, Head of Asia,Locust Walk
Founder & CEO, Eighty-Eighty Therapeutics

Mr. Yamamoto is a founder of Eighty-Eighty Therapeutics and H&L Consulting, and currently working at Locust Walk, investment banking,  as the managing director, head of Asia.
He has more than 15 years of business management expertise in pharmaceutical companies in Pan-Asia.
Previously, Mr. Yamamoto worked at SanBio as Corporate Officer, where he was in charge of expanding regenerative medicine in Japan and Asia. Prior to SanBio, he was Managing Director of Santen Asia/Inida and Vice President of Santen China, where he managed the launch and business operations in the ASEAN region and in China.
Mr. Yamamoto started his career at Eisai Co., Ltd., and AbbVie Inc., where he led Japan sales and Asian business development activities.
Mr. Yamamoto holds a degree in chemical engineering from Doshisha University and an MBA from the National University of Singapore.
Outside of work, Mr. Yamamoto enjoys traveling all over the world for wine collection and watching football.

Speech title & Synopsis

What is the most effective way to achieve strategic alliances?
- My 2022 experience -

For Biotech companies, strategic partnerships with pharmaceutical companies are very important. In addition, it is becoming increasingly difficult for pharmaceutical companies to take on the entire drug discovery process, from research to clinical development to commercialization.
 
For Biotech and pharmaceutical companies, strategic alliances require maximizing the use of various resources, information, and networks, including VC, PE, and shareholders.
 
For example, the way the initial outreach emailed can make a big difference in the final outcome. In fact, when top 20 Japanese pharmaceutical companies contact U.S. biotech companies, they often do not reply to their emails.
 
In this speech, I will show you how to effectively implement and prepare for strategic alliances. I hope you will make use of it in Sell-side, Buy-side, Fund-raising, M&A, etc.